Pacific Sun Financial’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.22M Buy
1,324
+4
+0.3% +$4.05K 0.59% 49
2025
Q4
$1.42M Sell
1,320
-52
-4% -$49.7K 0.68% 40
2025
Q3
$1.05M Buy
1,372
+5
+0.4% +$3.72K 0.51% 60
2025
Q2
$1.07M Buy
1,367
+5
+0.4% +$3.88K 0.56% 54
2025
Q1
$1.12M Sell
1,362
-3
-0.2% -$2.5K 0.64% 48
2024
Q4
$1.05M Sell
1,365
-75
-5% -$62.1K 0.57% 51
2024
Q3
$1.28M Hold
1,440
0.7% 41
2024
Q2
$1.3M Hold
1,440
0.77% 39
2024
Q1
$1.12M Buy
1,440
+1,000
+227% +$712K 0.65% 47
2023
Q4
$256K Sell
440
-40
-8% -$23.3K 0.16% 147
2023
Q3
$258K Buy
+480
New +$247K 0.18% 141
2022
Q4
Sell
-1,480
Closed -$479K 178
2022
Q3
$479K Sell
1,480
-100
-6% -$31.7K 0.34% 97
2022
Q2
$512K Buy
1,580
+100
+7% +$30K 0.34% 94
2022
Q1
$424K Hold
1,480
0.23% 119
2021
Q4
$409K Sell
1,480
-55
-4% -$13.9K 0.22% 119
2021
Q3
$355K Buy
+1,535
New +$379K 0.2% 123
2018
Q1
Sell
-12,890
Closed -$1.09M 164
2017
Q4
$1.09M Buy
+12,890
New +$1.1M 0.6% 62

Other funds holding LLY

Pacific Sun Financial's LLY Position: Q1 2026 in Review

Pacific Sun Financial increased its Eli Lilly (LLY) stake by 0.3% in Q1 2026, buying an estimated $4.05K and bringing the position to 1,324 shares worth $1.22M. The position accounts for 0.59% of the portfolio, ranked #49.

Pacific Sun Financial first reported a position in LLY in Q4 2017 and has held it in 17 quarters since. The position peaked at $1.42M in Q4 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Pacific Sun Financial held 1,324 shares of Eli Lilly worth $1.22M as of Q1 2026.
  • Pacific Sun Financial bought 4 Eli Lilly shares in Q1 2026, an estimated $4.05K.
  • Eli Lilly made up 0.59% of Pacific Sun Financial's portfolio in Q1 2026, its #49 holding.
  • Pacific Sun Financial first reported a position in Eli Lilly in Q4 2017 and has held it in 17 quarters since.
  • Pacific Sun Financial's Eli Lilly position peaked at $1.42M in Q4 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Pacific Sun Financial's 13F filing for Q1 2026, filed 8 May 2026.